This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
The approval was granted by Agenzia Italiana del Farmaco
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
The development comes as stroke remains one of the world’s biggest health threats
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Subscribe To Our Newsletter & Stay Updated
